

# Dr Rahul Kushwah on how Predictmedix's AI driven Safe Entry Station detects disease and impairment symptoms

written by InvestorNews | February 4, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF) about Predictmedix's artificial intelligence powered infectious disease symptom screening solution for workplace health and safety.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Dr. Kushwah went on to say, "You can open facilities and workplaces but it is about bringing in technologies that can create safety bubbles in those places. That is where our infectious disease symptom screening solution or Safe Entry Station comes into play. The technology can identify a host of symptoms associated with COVID-19."

Speaking on the competitive advantages of Predictmedix's Safe Entry Station Dr. Kushwah said, "It looks at several symptoms associated with infectious diseases. So, it is not just another fever scanner. At the same time, there is a deep learning algorithm that runs in the background. **As more and more people pass through the system the system keeps on getting smarter.**"

To watch the full interview, [click here](#)

## About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company

developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease.

To learn more about Predictmedix Inc., [click here](#)

***Disclaimer:*** *Predictmedix Inc. is an advertorial member of InvestorIntel Corp.*

---

# Dr Rahul Kushwah on infectious disease symptom screening technology, sales and the Predictmedix partnerships in play

written by InvestorNews | February 4, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF) about ramping up their sales and business development efforts and provides an update on partnerships already in play.

Predictmedix is dedicated to health and wellness using artificial intelligence powered technologies. In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Dr. Kushwah went on to provide an update on the Safe Entry Stations powered by Predictmedix's proprietary infectious disease symptom screening technology. "We have had successful deployment with several companies including Fortune 500 companies such as Indian Oil," Dr. Kushwah said.

Predictmedix has been actively [signing partnerships](#) with some of the major healthcare providers. "We have partnered with Max Healthcare which is one of the largest groups of hospitals in Asia...At the same time we have just deployed our technology at MGM Hospital in Mumbai and that is one of the largest COVID-19 clinics in India."

To watch the full interview, [click here](#)

## About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.

To learn more about Predictmedix Inc., [click here](#)

***Disclaimer:*** *Predictmedix Inc. is an advertorial member of InvestorIntel Corp.*

---

# Punching above their weight, Predictmedix keeps nailing the heavyweight health tech partnerships

written by InvestorNews | February 4, 2021

As the world shifts to a “new” normal, employee and customer screenings will be commonplace and [Predictmedix Inc. \(CSE: PMED | OTCQB: PMEDF\)](#) and its solutions are leading the way.

The recent announcement by Predictmedix, regarding the partnership with McGill University, is another example of the relationships that Dr. Rahul Kushwah, COO of Predictmedix, is developing with major corporations and leading healthcare providers as it rolls out Artificial Intelligence (“AI”) health tech solutions.

Predictmedix aims to improve the healthcare system through innovative and cutting-edge digital health technologies. Currently, Predictmedix AI solutions focus on infectious-disease screenings, impairment detection, and remote patient monitoring.

The Company’s products use facial, thermal, video, and audio recognition technologies to determine when individuals are impaired, suffering from an infectious disease, or mental illness. One solution focuses on mass and rapid AI-based screening for COVID-19 symptoms.

**Partnerships, Pilots, Trials and Installs – Where Does Predictmedix Find the Time**

Earlier this month, Predictmedix announced partnering with a research group led by Dr. Samira Rahimi from McGill University's Department of Family Medicine.

Dr. Rahimi's research group will be working with Predictmedix and its three industry verticals: (1) screening for infectious disease associated symptoms; (2) screening for alcohol or cannabis impairment; and, (3) mental health screening.

Dr. Rahul Kushwah commented, "We are extremely excited with the partnership with Dr. Samira Rahimi's team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals."

The announcement with McGill is just the latest in a series of pilot projects, partnerships, and product rollouts that Predictmedix has successfully executed this year. Predictmedix believes that it is well-positioned for growth and to capture the current sales momentum into Q1/2021.

Recently, the Company announced that it will be deploying its COVID-19 screening technology along with alcohol and impairment screening technology at [Indian Oil Corporation Ltd \(NSE:IOC.NS\)](#), a multi-billion dollar India-based oil company, and the deployment of its mass screening technology for COVID-19 with [Max Healthcare](#), one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.

Predictmedix also announced a collaboration with India-tech giant [Tech Mahindra Ltd \(NSE: TECHM\)](#), to incorporate Predictmedix's impairment detection technology and COVID-19 solutions into Tech Mahindra's suite of technologies offered for workplace health and safety across the globe.

Closer to home, the Company, in conjunction with its partner

[Juiceworks Exhibits](#), successfully deployed its infectious disease screening technology at [Flow Water](#) in Aurora, Ontario, and a 24-hour pharmacy in Montreal, Quebec.

Used by employees on a daily basis, Predictmedix's gateway screens individuals, in a non-invasive way, as they walk through and it triggers an alarm if symptoms associated with an infectious disease are detected, such as COVID-19, or signs of impairment due to alcohol or cannabis use.

The screening product consists of hardware, software, multi-spectral cameras, and specialized sensors that are assembled into a gateway, much like a metal detector in an airport, and communicates with Predictmedix's AI model in the cloud.

### **Remote Patient Monitoring & Telehealth Enterprise Platform with Mobile Wellbeing Acquisition**

In June, Predictmedix acquired Mobile Wellbeing, a remote patient monitoring platform, which is strategic for the Company in creating an enterprise platform and allows Predictmedix to enter the telehealth and clinical trials markets.

According to a recent by study Adroit Market Research, the Remote Patient Monitoring Market is anticipated to reach US\$1.9 billion by 2026, growing at a CAGR of almost 13% from 2020 to 2026.

With current stay-at-home orders due to the COVID-19 health crisis, clinical drug trials shifted to remote monitoring from on-site monitoring. The U.S. Food and Drug Administration ("FDA") now supports remote monitoring for oversight of clinical sites.

In addition, the Mobile Wellbeing platform is equally suited for use in long-term care facilities to care for elderly patients.

Big Data features include assisted monitoring that allows for data collection, transmission, evaluation, and notification. Utilizing the latest off-the-shelf wearables, the platform has shown benefits such as improved patient health and also lowered the cost of care through remote monitoring.

Predictmedix anticipates the commercial launch of its remote patient monitoring platform Q1/2021 with some key, large-scale deployments in North America and Asia.

Predictmedix is currently trading at \$0.46 with a market cap of \$46.5M but with billion-dollar partners and a pipeline of projects in Q1/2021, clearly ready for a re-rating.

---

## **Dr. Rahul Kushwah on Predictmedix's remote patient monitoring technology and Mobile Wellbeing**

written by InvestorNews | February 4, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF), about their infectious disease screening technology and remote patient monitoring platform, Mobile Wellbeing.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Dr. Kushwah talked about the successful North American

deployment of Predictmedix's infectious disease screening technology at Flow Water in Aurora, Ontario. Dr. Kushwah went on to provide an update on their Mobile Wellbeing platform. "It is in telehealth and telemedicine business, but it does more than that." He continued, "It does something which is referred to as remote patient monitoring." Dr. Kushwah added that Predictmedix is targeting clinical trials and long-term care markets with its Mobile Wellbeing platform. FDA now has very strong guidance which is promoting remote patient monitoring and that brings Predictmedix's technology to the forefront.

In the interview Dr. Kushwah also said that Accenture, a multinational professional services company and a Fortune Global 500 company, recently wrote about how Predictmedix is innovating to help with the current COVID-19 pandemic ([click here to read the article](#)). "It should indicate to shareholders that not only our technology is disruptive but we are clearly in a market segment which is not only ballooning right now but is going to be huge as time goes by." Dr. Kushwah commented. To watch the full interview, [click here](#)

### **About Predictmedix**

Predictmedix develops AI technologies focused on areas which include screening for impairment, infectious disease and mental health, and a remote patient monitoring/telehealth platform, all of which play a vital role in health and safety. Their technologies are timely to assist with the current pandemic, as well as having lasting utility that goes beyond the current crisis, extending into workplace health, safety and compliance.

To learn more about Predictmedix Inc., [click here](#)

**Disclaimer:** *Predictmedix Inc. is an advertorial member of InvestorIntel Corp.*

---

# Predictmedix is starting to commercialize as AI health screening & monitoring takes off

written by InvestorNews | February 4, 2021

Health screening is big business these days. The latest way is using Artificial Intelligence (AI) to mass screen and/or monitor for impairment and various disease states, including COVID-19.

One company is now starting to commercialize their technology, winning contracts and forming distribution partners all around the globe. That company is [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF).

The global market size for AI in healthcare in 2017 was US\$1.4b and is forecast to rise to reach [US\\$28b](#) by 2025, for **an approximate 20 fold increase in just 8 years**. Healthcare screening and monitoring using AI can play a key role.

**The global market for artificial intelligence (AI) in healthcare is forecast to take off**



## [Source](#)

Predictmedix has developed leading disruptive AI technology in impairment detection and healthcare screenings. Their AI powered products use facial, thermal, video and audio recognition

technologies to determine when individuals are suffering from infectious disease, are drug or alcohol impaired, or have a mental illness. The Predictmedix screening devices are backed up by a remote patient monitoring platform.



## [Source](#)

### **Predictmedix's latest achievements to commercialize their screening AI technology**

- [October 1, 2020](#) – Partnered with Versus Systems to develop tools for clinical trials, in particular on-site monitoring to ensure human subject protection, data integrity, and quality. The news release [states](#): “This will allow Predictmedix to enter a new industry vertical of clinical trials which is a \$40 billion market opportunity as estimated by Fortune Business Insights.”
- [September 3, 2020](#) – Predictmedix Inc. and Juiceworks Exhibits provide safe entry solutions to facility managers at IFMA World Workplace in Texas.
- [August 17, 2020](#) – Predictmedix Inc. and Juiceworks Exhibits announce COVID-19 technology deployments in North America.
- [August 12, 2020](#) – Deployment of Impairment Screening along with COVID-19 symptom screening technology at Indian Oil Corporation.
- [July 7, 2020](#) – Sales/distributor 1 year contract with Taurus Medical in the United Kingdom. Taurus Medical manufacture and market over 1,500 products for the diagnosis, treatment and monitoring of respiratory conditions. They are a supplier for the UK National Health Service. Taurus is offering Predictmedix COVID-19 mass screening entry modules to the healthcare, retail, and the

entertainment sector in the UK.

- [June 26, 2020](#) – Teamed up with Tech Mahindra who will resell Predictmedix to their global client base. Tech Mahindra is a \$4.9 billion dollar company owned by Mahindra Group. Tech Mahindra is operational across 90 countries, helping 973 global customers including Fortune 500 companies.

Regarding the Indian Oil Corporation contract Predictmedix [state](#):

“The deployment of our COVID-19 screening and impairment technology at IOCL which is a fortune 500 company marks our entry into the Oil & Gas sector which is one of the largest industrial sectors and it further highlights the market need for the suite of technologies developed by Predictmedix.”

Now that’s a very busy past 5 months. The model of using well known brands (Juiceworks Exhibits, Taurus Medical, Tech Mahindra) with large distribution networks should make for a faster and more successful commercialization. Product deployment at large corporations such as Indian Oil Corporation show solid early demand for the Predictmedix product.

Predictmedix operates under a SaaS model. Clients pay a monthly fee based on tiered volume of screenings or by number of device feeds. Both pricing options provide Predictmedix with recurring monthly revenue and multi-year contracts.

Right now as COVID-19 cases approach [40 million](#) (and 1.2 million deaths) it certainly looks like there is a massive potential market for Predictmedix’s COVID-19 Safe Entry Solutions. This could be the product that rapidly launches Predictmedix into the AI health screening market. You can read more on that [here](#).

Predictmedix current market cap is C\$58m. The Company looks to

have plenty of growth opportunities ahead as it strives to capture a share of the forecast [US\\$28b](#) AI healthcare market by 2025.

## Further learning

- [Predictmedix's Dr. Rahul Kushwah on using AI to solve real world problems](#)

---

# Predictmedix's Dr. Rahul Kushwah on using AI to solve real world problems

written by InvestorNews | February 4, 2021

## Using artificial intelligence to mass screen for COVID-19

"It's about the different verticals that we are addressing with Predictmedix," says Dr. Rahul Kushwah, Co-Founder and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF). "We are an artificial intelligence company and we are solving real-world problems."

In an interview with InvestorIntel's Tracy Weslosky, Dr. Kushwah explains three of their vertical markets: "COVID-19 pandemic, we are all in the midst of it and we have a technology which is to mass screen for COVID-19. Similarly, impairment is a big issue when it comes to workplace and law enforcement and we have a solution for that. And the third vertical is mental illnesses. \$300 billion spent in the US last year and there is so much subjectivity that goes into diagnosis and we are

developing a solution to diagnose mental illnesses.”

“We have developed modules which look like metal detectors,” Dr. Kushwah continued. “You walk through these modules and on the other end you have a green or red light. If someone is identified to be positive for COVID-19 symptoms a red light goes off – if not then you get a green light.” He continued, “it is a tool that you can use for mass screening in airports, transit hubs, malls, office building, government buildings, or anywhere you can imagine where you have big flow of people.” Dr. Kushwah also discusses the pitfalls of current telehealth and telemedicine platforms, and Predictmedix’s innovative solutions.

To access the complete interview, [click here](#)

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

---

## **Predictmedix’s Dr. Kushwah on how AI technology for mass screening of COVID-19 is here**

written by InvestorNews | February 4, 2021

“We have developed a technology to screening for COVID-19 and the key is, it is a mass screening technology. The technology works with multispectral imaging and our AI algorithms, which are patent pending and sit on a cloud, and they communicate directly with the multispectral cameras. These cameras can be installed and as people are passing by, the technology will just screen them for COVID-19.” States Dr. Rahul Kushwah, Co-Founder

and COO of [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF), in an interview with InvestorIntel's Tracy Weslosky.

Dr. Kushwah went on to say that the technology can be deployed in places where there is movement of large number of people like airports, shopping centers, malls, arenas, transit hubs, etc. He added, "If you want to control the next wave you have to ensure that there is no transmission of infection and the only way you can do that is by containment and to contain you have to identify."

Dr. Kushwah also provided an update on the appointment of Microsoft Director of Business Development for AI solutions, Kapil Raval, as the Chairman of the Advisory Board. He said that Predictmedix is working very closely with the Indian Institute of Technology to scale up its technologies. Dr. Kushwah also said that Predictmedix has deployed its mass screening technology for COVID-19 with Max Healthcare. He continued, "Max Healthcare is one the largest healthcare group in South Asia...They have 14 hospitals with over 3000 doctors, and we have deployed our technology at their facilities. That is a phenomenal validation to what we have developed."

To access the complete interview, [click here](#)

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.

---

## The Perfect Market Storm:

# Critical Materials, Cleantech and COVID-19

written by Tracy Weslosky | February 4, 2021

There seems to be a misguided notion (with some) that isolation means we have more time to waste. Far from reality, I am certain that many of you, like me are looking at your inbox wondering where or how to wade into the depth of quality deals and opportunities upon us...

Would like to kick your morning coffee off with a special nod to our longstanding friends from [Avalon Advanced Materials Inc.](#) (TSX: AVL | OTCQB: AVLNF) whose \$AVL soared 50% yesterday. We have been supporters of #Avalon since Don Bubar first did an interview with me in 2009 (with Jack Lifton) and introduced me to rare earths. And indeed, there is news flow in the rare earths a-n-d throughout the critical materials sector that is literally ricocheting from source-to-source online...

## [How to follow?](#)

Jack Lifton, Clint Adam Smyth and I just launched the [TechnologyMetals.com](#) site to manage the influx of critical materials' news (and experts) we are communicating with regularly. Jack's interview with Dr. David Dreisinger on [Search Minerals Inc.](#) (TSXV: SMY) last week was purely outstanding (in my opinion) as he describes David as "the leading authority on solvent extraction process". This is a hot topic that we touch on in our weekly update that we just started...[click here to access a preview](#)

And associated technologies relating to cleantech? We saw [Exro Technologies Inc.](#) (CSE: XRO | OTCQB: EXROF) stock move up 30% yesterday! Interviewing CEO Sue Ozdemir on how Exro makes

“electric motors faster, stronger and greener” for InvestorIntel on Wednesday: we will get this up live as fast as we can!

Uranium continues to maintain a much-deserved interest, let me point you in the right direction for a quick update – Matt Bohlson’s piece from last week titled, [The DoE’s plan to rebuild the uranium sector and ‘pull America’s nuclear industrial base back from the brink of collapse’...](#) reinforces the sustainability themes we are touting on the Technology Metals Show. Arranging interviews as we speak with Mark Chalmers of [Energy Fuels Inc.](#) (NYSE: UUUU | TSX: EFR) and Jeff Klenda of [Ur-Energy Inc.](#) (NYSE: URG | TSX: URE) as they “stand to be the major beneficiaries, especially given they started the whole S232 petition back in January 2018” you should see those live on InvestorIntel next week.

And yes, we are following the biotech and life sciences market. If you subscribe to our AI driven market updates on InvestorChannel.com – you can catch the 20 companies, we are following in the race for vaccinations...[click here](#)

Speaking of AI technology, we would like to ensure that you are aware of the news that was put out by [Predictmedix Inc.](#) (CSE: PMED | OTCQB: PMEDF) yesterday titled – [Predictmedix Files Patent for Mass Screening for Infectious Diseases Such As #COVID19](#)



1 YR stock Chart for Predictmedix Inc. (CSE: PMED) – Source: TD Waterhouse

And speaking on the war against the COVID-19, [StageZero Life Sciences Ltd.](#) (TSX: SZLS) put out the following news on April 20<sup>th</sup> [StageZero Life Sciences Initiates Testing for COVID-19 In the USA](#)

Remember, click here to subscribe to the [InvestorChannel](#) for daily market updates on the Canadian, US and Hong Kong markets – and to follow InvestorIntel's stock watchlist for Gold, Uranium, Rare Earths and of course, COVID-19...